| Literature DB >> 36187943 |
Pu Cui1, Lijun Liu1, Zhongdi Huang1, Shuping Shi1, Kun Kong1, Yinglao Zhang1,2.
Abstract
Insect-associated fungi are a potentially rich source of novel natural products with antibacterial activity. Here, we investigated the community composition and phylogenetic diversity of gut-associated fungi of the dragonfly (Crocothemis Servilia) using a combination of culture-dependent and culture-independent methods. A total of 42 fungal isolates were obtained from the guts of the dragonfly, which belonged to four classes and thirteen different genera. Amplicon sequencing analyses revealed that the fungal communities were more diverse, and a total of 136 genera were identified and dominated by the genera Wojnowiciella and Phoma. The antibacterial bioassay showed that five fungal crude extracts of representative isolates have shown antibacterial activities. Among them, the extract of Phoma sp. QTH17 showed the best antibacterial activities against Escherichia coli, Micrococcus tetragenus, and Staphylococcus aureus with the disc diameter of inhibition zone diameter (IZD) of 6.50, 10.80, and 8.70 mm, respectively. Chemical analysis of Phoma sp. QTH17 led to the discovery of five known compounds, including ergosterol (1), 3-Chlorogentisyl alcohol (2), epoxydon (3), epoxydon 6-methylsalicylate ester (4) and mannitol (5). Among them, the compound 3 exhibited potent antibacterial activities against E. coli, M. tetragenus, and S. aureus with the IZD of 7.00, 14.00, and 12.50 mm, respectively, which were slightly weaker than those of the positive gentamicin sulfate with the IZD of 11.13, 18.30, and 12.13 mm, respectively. In conclusion, our results confirmed that the diversity of gut-associated fungi of C. Servilia could be expected to explore the resource of new species and antibacterial substances.Entities:
Keywords: Crocothemis servilia; antibacterial activity; fungal diversity; insect-associated fungi; secondary metabolites
Year: 2022 PMID: 36187943 PMCID: PMC9523248 DOI: 10.3389/fmicb.2022.970990
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Phylogenetic analysis of cultivable fungi associated with gut of C. Servilia.
| Isolate code | Closest match | Accession no. | Coverage/max ident | GenBank no. |
| QTH36 |
| 99/99 |
| |
| QTSY23 |
| 99/100 |
| |
| QTY84 |
|
| 99/99 |
|
| QTSY9 |
|
| 99/99 |
|
| QTSY15 |
|
| 99/99 |
|
| QTSY22 |
|
| 99/99 |
|
| QTSY24 |
|
| 99/100 |
|
| QTY2 |
|
| 99/99 |
|
| QTH11 |
|
| 99/99 |
|
| QTH22 |
|
| 99/100 |
|
| QTY16 |
|
| 99/99 |
|
| QTH27 |
| 99/99 |
| |
| QTH21 |
| 99/99 |
| |
| QTH15 |
| 99/99 |
| |
| QTY4 |
| 100/99 |
| |
| QTH17 |
| 97/99 |
| |
| QTH12 |
|
| 92/99 |
|
| QTH2 |
|
| 92/99 |
|
| QTH4 |
|
| 98/99 |
|
| QTH14 |
|
| 99/99 |
|
|
|
| 98/98 |
| |
| QTY69 |
|
| 99/99 |
|
| QTY17 |
| 100/99 |
| |
| QTH40 |
|
| 99/100 |
|
| QTH41 |
|
| 100/99 |
|
| QTY61 |
|
| 98/99 |
|
| QTY55 |
| 99/100 |
| |
| QTSY25 |
|
| 99/99 |
|
| QTH32 |
|
| 98/99 |
|
| QTH24 |
|
| 98/99 |
|
| QTY76 |
|
| 99/100 |
|
| QTY60 |
|
| 99/100 |
|
| QTH38 |
|
| 99/99 |
|
| QTY62 |
|
| 100/99 |
|
| QTH28 |
|
| 99/99 |
|
|
|
| 99/98 |
| |
| QTH34 |
|
| 99/99 |
|
| QTH35 |
|
| 100/99 |
|
| QTH29 |
|
| 98/99 |
|
| QTH37 |
|
| 98/99 |
|
| QTY77 |
|
| 97/99 |
|
| QTY72 |
|
| 97/99 |
|
*Potentially new species.
FIGURE 1Neighbor-joining phylogenetic tree of ITS rDNA sequences of gut-associated fungi.
FIGURE 2Analysis of culture-independent microbial communities. Relative abundance of phylum (A) and genus (B) within gut fungal communities.
Inhibition zone diameters of inhibiting effects of fungal extracts on three tested bacteria (mm).
| Proposed identity | Isolate code |
|
|
|
|
| QTH14 | NI | 7.20 ± 0.47 | NI |
| QTH15 | NI | 8.30 ± 0.82 | NI | |
| QTH17 | 6.50 ± 0.47 | 10.80 ± 0.00 | 8.70 ± 0.47 | |
| QTH21 | NI | 9.20 ± 0.24 | 8.20 ± 0.47 | |
|
| QTH31 | NI | NI | NI |
|
| QTH32 | NI | NI | NI |
| QTH36 | NI | NI | NI | |
|
| QTH41 | NI | NI | NI |
|
| QTY1 | NI | NI | NI |
| QTY4 | NI | NI | NI | |
| QTH27 | 7.00 ± 0.00 | 6.50 ± 0.00 | NI | |
| Gentamycin sulfate | 13.60 ± 0.47 | 16.50 ± 0.82 | 12.30 ± 0.47 |
aGentamycin sulfate as the positive control. “NI” means not inhibited; the concentration for the test is 30 μg/filter paper.
FIGURE 3The structure of compounds 1–5.
Inhibition zone diameter (mm) and minimum inhibitory concentration (MIC) values (μg/mL) of compounds against three tested bacteria.
| Compounds |
|
|
| |||
|
|
|
| ||||
| IZD | MIC | IZD | MIC | IZD | MIC | |
| 2 | NI | NT | 9.00 ± 0.05 | NT | NI | NT |
| 3 | 7.00 ± 0.03 | >100 | 14.00 ± 0.24 | >100 | 12.50 ± 0.20 | >100 |
| 4 | NI | >100 | NI | >100 | 11.00 ± 0.23 | >100 |
| Gentamycin sulfate | 11.13 ± 0.20 | >100 | 18.30 ± 0.31 | 12.5 | 12.13 ± 0.58 | 6.25 |
aResults are presented as the mean ± standard; “NI” means not inhibited; the concentration for the test is 30 μg/filter paper; “NT” means not tested. bGentamycin sulfate as the positive control.